Anna Raciborska
Anna Raciborska
Explore linked clinical trials.5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-07 | NCT07787429 | |
| To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-07 | NCT05968768 | |
| Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients | Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, histiocytosis, interstitial lung disease, lung disorder, lymphatic system disorder, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT04943224 | |
| Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging | Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, histiocytosis, interstitial lung disease, lung disorder, lymphatic system disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-07 | NCT04943211 | |
| Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis | Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, histiocytosis, interstitial lung disease, lung disorder, lymphatic system disorder, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT04943198 |